What is the official website of Astellas Pharma ?

The official website of Astellas Pharma is http://www.astellas.com/.

What is Astellas Pharma's cybersecurity risk score?

Astellas Pharma has an AI-generated cybersecurity risk score of 802 out of 1000, indicating a Good security posture according to Rankiteo's assessment.

How many security incidents has Astellas Pharma experienced?

According to Rankiteo, Astellas Pharma currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Astellas Pharma been affected by any supply chain cyber incidents ?

According to Rankiteo, Astellas Pharma has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Astellas Pharma have SOC 2 Type 1 certification ?

According to Rankiteo, Astellas Pharma is not certified under SOC 2 Type 1.

Does Astellas Pharma have SOC 2 Type 2 certification ?

According to Rankiteo, Astellas Pharma does not hold a SOC 2 Type 2 certification.

Does Astellas Pharma comply with GDPR ?

According to Rankiteo, Astellas Pharma is not listed as GDPR compliant.

Does Astellas Pharma have PCI DSS certification ?

According to Rankiteo, Astellas Pharma does not currently maintain PCI DSS compliance.

Does Astellas Pharma comply with HIPAA ?

According to Rankiteo, Astellas Pharma is not compliant with HIPAA regulations.

Does Astellas Pharma have ISO 27001 certification ?

According to Rankiteo,Astellas Pharma is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Astellas Pharma operate in ?

Astellas Pharma operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Astellas Pharma have ?

Astellas Pharma employs approximately 12,110 people worldwide.

Does Astellas Pharma own any subsidiaries ?

Astellas Pharma presently has no subsidiaries across any sectors.

How many LinkedIn followers does Astellas Pharma have ?

Astellas Pharma's official LinkedIn profile has approximately 671,790 followers.

What is the NAICS classification code for Astellas Pharma ?

Astellas Pharma is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Astellas Pharma have a Crunchbase profile ?

No, Astellas Pharma does not have a profile on Crunchbase.

Does Astellas Pharma have a LinkedIn profile ?

Yes, Astellas Pharma maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/astellaspharmainc.

How many cybersecurity incidents has Astellas Pharma experienced ?

As of July 21, 2026, Rankiteo reports that Astellas Pharma has not experienced any cybersecurity incidents.

How many peer or competitor companies does Astellas Pharma have ?

Astellas Pharma has an estimated 5,710 peer or competitor companies worldwide.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Astellas Pharma

Boost Score +25 with badge (5 left)

802

/1000

Good

827

/1000

Good

Astellas Pharma Vendor Cyber Rating & Cyber Score

astellas.com

Add Your Compliance Badge

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Astellas Pharma A.I CyberSecurity Scoring

Scoring History

Astellas Pharma

Astellas Pharma CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Astellas Pharma Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Astellas Pharma

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Astellas Pharma in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Astellas Pharma in 2026.

Incident Types Astellas Pharma vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Astellas Pharma in 2026.

Incident History - Astellas Pharma (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Astellas Pharma Subsidiaries

Astellas Pharma

Pharmaceutical Manufacturing

Website: http://www.astellas.com/

Company Size: 10,000+ employees

Astellas Gene TherapiesBiotechnology Research

Loading…

Astellas Pharma Similar Companies

Merck Group

merckgroup.com

This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trademark MERCK in the U.S. and Canada. _______________________________ We are Merck, a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Work your Magic and join Merck. Legal Disclaimer: www.merckgroup.com/en/legal-disclaimer.html Data Privacy Declaration: www.merckgroup.com/en/privacy-statement

Ipca Laboratories Limited

ipca.com

A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. - One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally - 15 APIs & 11 Formulations manufacturing facility across the globe Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis - Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA

AUROBINDO PHARMA LTD

aurobindo.com

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

Dr. Reddy's Laboratories

drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

Novartis

cb novartis.com

Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

PT Kalbe Farma, Tbk

kalbe.co.id

Established in 1966, PT Kalbe Farma Tbk. (“the Company” or “Kalbe”) has gone a long way from its humble beginnings as a garage-operated pharmaceutical business in North Jakarta. It has expanded by strategic acquisitions of pharmaceutical companies, building a leading brand positioning and reaching to international markets to transform itself into an integrated consumer health and nutrition enterprise to promote its mission to improve health for a better life. Kalbe expands its business interests and transformed itself to become a provider of an integrated healthcare solution through its 4 business divisions: the Prescription Pharmaceutical Division, Consumer Health Division, Nutritionals Division and Distribution and Logistics Division. These business divisions manage an extensive portfolio of prescription pharmaceuticals and OTC drugs, energy drink and nutrition products, as well as a robust distribution arm serving over one million outlets across Indonesia’s vast archipelago. In the international market, the Company has established its footprint in ASEAN countries, Nigeria, and South Africa, positioning Kalbe as a national pharmaceutical company with a competitive edge in the export market. Kalbe Farma has established a robust research and development activities in leading edge generic drug formulation and continuous development of innovative consumer and nutritional products. Through strategic alliances with international partners, Kalbe have also started to support several successful research and development venture working on cancer drugs, stem cells and biotechnology research. With 17,000 employees, Kalbe Farma is the largest healthcare provider in Indonesia, with unrivaled marketing, branding, distribution, financial strength and research and development expertise. Kalbe Farma is also the largest publicly-listed pharmaceutical company in Southeast Asia, commanding a market capitalization of Rp71.0 trillion and sales turnover Rp21.0 trillion by end of 2018.

Loading…

NEWS

Astellas Pharma CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

January 03, 2026 08:00 AM

Five trends shaping modern business services centers in Poland

In 2026 some service centers will close or cut headcount, while smaller and more specialized will emerge. A major AI-driven shift is ahead.

Read Article

September 23, 2024 07:00 AM

The White House, Microsoft, SaS, Foley Hoag & Astellas Offer AI Guidance to Investors. Part One: The Present

Before companies and investors look towards the future, they must first understand the opportunities and challenges AI presents to them.

Read Article

May 04, 2023 06:05 PM

Astellas acquires Iveric bio

Jones Day advised Astellas Pharma Inc. in the $5.9 billion cash acquisition of Iveric bio, Inc., a science-driven biopharmaceutical company focused on the...

Read Article

January 30, 2023 08:00 AM

Microsoft surpasses $20B in security revenue as enterprise customers consolidate

The company's cybersecurity business is growing, but CEO Satya Nadella warned that customers, in an uncertain economy, are exercising...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-15905

SUMMARY

Use after free in Aura in Google Chrome prior to 150.0.7871.128 allowed a local attacker to potentially exploit heap corruption via a malicious file. (Chromium security severity: High)

Published

Date2026-07-20

Updated

Date2026-07-20

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-15904

SUMMARY

Use after free in Ozone in Google Chrome on Linux prior to 150.0.7871.128 allowed a remote attacker who convinced a user to engage in specific UI gestures to potentially exploit heap corruption via a crafted HTML page. (Chromium security severity: High)

Published

Date2026-07-20

Updated

Date2026-07-20

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-15903

SUMMARY

Out of bounds read and write in V8 in Google Chrome prior to 150.0.7871.128 allowed a remote attacker to execute arbitrary code inside a sandbox via a crafted HTML page. (Chromium security severity: High)

Published

Date2026-07-20

Updated

Date2026-07-20

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-15902

SUMMARY

Use after free in Cast in Google Chrome prior to 150.0.7871.128 allowed a remote attacker to execute arbitrary code inside a sandbox via a crafted HTML page. (Chromium security severity: High)

Published

Date2026-07-20

Updated

Date2026-07-20

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

CVE-2026-15901

SUMMARY

Use after free in Network in Google Chrome prior to 150.0.7871.128 allowed a remote attacker to potentially exploit heap corruption via a crafted HTML page. (Chromium security severity: Critical)

Published

Date2026-07-20

Updated

Date2026-07-20

RISK INFORMATION (Score: )

Impact Score

Exploitability

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…